Fulgent Genetics to Acquire Bako Diagnostics and StrataDx

Eurobio Scientific Acquires CareDx Lab Products Division

April 16, 2026

Healthcare Services

Eurobio Scientific entered into a definitive agreement to acquire CareDx’s Lab Products transplant lab products division for €145 million (about $170 million) in cash. The deal will integrate the acquired Lab Products portfolio into Eurobio’s GenDx operations and is intended to expand GenDx’s comprehensive transplantation IVD workflow, from pre-transplant HLA typing to post-transplant monitoring solutions.

LabGenomics USA LLC Acquires QDx Pathology

September 5, 2023

Healthcare Services

LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Fulgent Genetics Acquires Inform Diagnostics from Avista Capital Partners

April 18, 2022

Healthcare Services

Fulgent Genetics (NASDAQ: FLGT) closed its acquisition of Inform Diagnostics, a national independent pathology laboratory headquartered in Irving, Texas, for approximately $170 million (subject to adjustments). Avista Capital Partners had carved out and grown Inform Diagnostics before selling it to Fulgent, enabling Fulgent to expand into pathology test menus and nationwide commercial infrastructure.

P4 Diagnostix Acquires Assets of Strand Diagnostics (know error)

February 11, 2020

Healthcare Services

P4 Diagnostix announced the acquisition of the assets of Strand Diagnostics, the creator of the know error DNA specimen provenance testing system. P4 said it will resume testing, supplies and logistics for know error clients and immediately offer Strand's UroSeq assay to expand P4's molecular testing capabilities for urology and oncology customers.